Gravigny, France

Bruno Criere

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 43(Granted Patents)


Company Filing History:


Years Active: 2006-2014

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Bruno Criere: Innovator in Pharmaceutical Composition

Introduction

Bruno Criere, an accomplished inventor based in Gravigny, France, has made significant contributions to the pharmaceutical industry. With a total of six patents to his name, he has focused on enhancing the bioavailability of active pharmaceutical ingredients, particularly through innovative formulations.

Latest Patents

One of Criere's latest patents involves a pharmaceutical composition that contains micronized fenofibrate, a surfactant, and a binding cellulose derivative, specifically hydroxypropylmethylcellulose. This innovative combination enhances the bioavailability of fenofibrate while maintaining a composition where the cellulose derivative represents less than 20 weight percent. The preparation method of this formulation is noteworthy for not using any organic solvents, highlighting Criere's commitment to environmentally friendly practices in drug development.

Career Highlights

Throughout his career, Bruno Criere has worked with prominent companies in the pharmaceutical sector, including Ethypharm and Laboratoires Des Produits Ethiques Ethypharm. His expertise and innovative approaches have positioned him as a key player in the development of advanced pharmaceutical solutions.

Collaborations

Criere has collaborated with notable professionals in the industry, including Pascal Suplie and Philippe Chenevier. These partnerships have allowed him to further expand his research and contribute to significant advancements in pharmaceutical compositions.

Conclusion

Bruno Criere's dedication to innovation has established him as a respected inventor in the realm of pharmaceuticals. With his focus on improving the efficacy of drug formulations, he continues to impact the industry positively, paving the way for new and improved therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…